Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · Real-Time Price · USD
1.930
-0.030 (-1.53%)
At close: Aug 1, 2025, 4:00 PM
1.926
-0.004 (-0.21%)
After-hours: Aug 1, 2025, 7:58 PM EDT
-1.53%
Market Cap82.71M
Revenue (ttm)n/a
Net Income (ttm)21.12M
Shares Out 42.85M
EPS (ttm)0.83
PE Ratio2.33
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume669,878
Open1.950
Previous Close1.960
Day's Range1.860 - 1.960
52-Week Range0.870 - 8.320
Beta0.27
AnalystsStrong Buy
Price Target9.60 (+397.41%)
Earnings DateAug 13, 2025

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and change... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2016
Employees 23
Stock Exchange NASDAQ
Ticker Symbol OTLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price target is $9.6, which is an increase of 397.41% from the latest price.

Price Target
$9.6
(397.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...

10 days ago - GlobeNewsWire

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care f...

12 days ago - GlobeNewsWire

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies

4 weeks ago - GlobeNewsWire

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...

6 weeks ago - GlobeNewsWire

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...

7 weeks ago - GlobeNewsWire

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-...

2 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret...

2 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret...

2 months ago - GlobeNewsWire

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret...

2 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieve...

4 months ago - GlobeNewsWire

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd...

5 months ago - GlobeNewsWire

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in t...

5 months ago - GlobeNewsWire

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025 LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Ge...

6 months ago - GlobeNewsWire

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial

6 months ago - GlobeNewsWire

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd...

6 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd...

6 months ago - GlobeNewsWire

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd...

6 months ago - GlobeNewsWire

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet...

Other symbols: NVS
7 months ago - Benzinga

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the E...

7 months ago - GlobeNewsWire

Top 3 Health Care Stocks That Could Blast Off This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: INORCKT
7 months ago - Benzinga

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

7 months ago - GlobeNewsWire

Outlook Therapeutics® Streamlines Operations

ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

8 months ago - GlobeNewsWire

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of w...

8 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Executive Leadership Transition

ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

8 months ago - GlobeNewsWire

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.

8 months ago - Benzinga